Celtaxsys, Inc. Information

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. Our flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response. It is well known that an over-stimulated inflammatory response is the primary catalyst for the excessive morbidity and premature mortality associated with CF. We aim to investigate whether treatment with acebilustat, in conjunction with existing therapies, helps patients return to homeostasis, or a more “normalized” immune response. A more normalized immune response could lead to improved lung function and better quality of life for patients living with CF.